NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy.
Saved in:
| Title: | NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy. |
|---|---|
| Authors: | Liu X; The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.; Department of Oncology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China., Wang P; Department of Oncology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China. peipeiwang2016@163.com.; School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, Guangdong, China. peipeiwang2016@163.com., Liu G; The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China. eyglliu@scut.edu.cn.; Department of Oncology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China. eyglliu@scut.edu.cn. |
| Source: | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2025 Apr; Vol. 27 (4), pp. 1529-1538. Date of Electronic Publication: 2024 Sep 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
